121 related articles for article (PubMed ID: 38557537)
1. Evaluation of Serum CA 19-9 as a Diagnostic Marker for Pancreatic Malignancy.
Ahmed SMF; Ullah AKM; Mohammed S; Chowdhury ASM; Haque MM; Rana AMM
Mymensingh Med J; 2024 Apr; 33(2):533-539. PubMed ID: 38557537
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
3. Serum LDH and CA-125: Markers for Diagnosis of Ovarian Malignancy.
Deeba F; Khatun S; Alam MM; Shahida SM
Mymensingh Med J; 2015 Apr; 24(2):334-40. PubMed ID: 26007262
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Thyroid Malignancies by Thyroid Auto Antibodies.
Rakib SA; Sharif SB; Nahar A; Alam SM
Mymensingh Med J; 2018 Jul; 27(3):585-595. PubMed ID: 30141450
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer.
Rashid MM; Alam AK; Habib AK; Rahman H; Hossain AK; Salam MA; Rahman S
Bangladesh Med Res Counc Bull; 2012 Dec; 38(3):90-3. PubMed ID: 23540183
[TBL] [Abstract][Full Text] [Related]
6. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Serum Gamma Glutamyl Transpeptidase (GGT) for Early Diagnosis of Biliary Atresia.
Haque MA; Karim MB; Sultana K; Hasan MS; Hussain F; Musabbir N; Anwar SA
Mymensingh Med J; 2023 Jan; 32(1):193-199. PubMed ID: 36594320
[TBL] [Abstract][Full Text] [Related]
8. Predictors of malignancy in pancreatic head mass: a prospective study.
Sivaraman A; Muthukrishnan A; Boopathy Senguttvan N; Anil Suchak S; Kannan U
Pan Afr Med J; 2011; 9():30. PubMed ID: 22145063
[TBL] [Abstract][Full Text] [Related]
9. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
11. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
[TBL] [Abstract][Full Text] [Related]
12. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
13. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
14. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
15. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.
Jeoung HY; Choi HS; Lim YS; Lee MY; Kim SA; Han SJ; Ahn TG; Choi SJ
J Gynecol Oncol; 2008 Dec; 19(4):229-35. PubMed ID: 19471578
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.
Molina V; Visa L; Conill C; Navarro S; Escudero JM; Auge JM; Filella X; Lopez-Boado MA; Ferrer J; Fernandez-Cruz L; Molina R
Tumour Biol; 2012 Jun; 33(3):799-807. PubMed ID: 22203495
[TBL] [Abstract][Full Text] [Related]
18. [A comparative study on serum immunoglobulin and tumor marker levels in the patients with autoimmune pancreatitis and pancreatobiliary malignancies].
Yoon H; Kim MH; Won SH; Park DH; Lee SS; Seo DW; Lee SK
Korean J Gastroenterol; 2013 Jun; 61(6):327-32. PubMed ID: 23877213
[TBL] [Abstract][Full Text] [Related]
19. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
20. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses.
Alcázar JL; Errasti T; Zornoza A; Mínguez JA; Galán MJ
Int J Gynaecol Obstet; 1999 Sep; 66(3):255-61. PubMed ID: 10580673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
